De Maeyer Roel P H, van de Merwe Rachel C, Louie Rikah, Bracken Olivia V, Devine Oliver P, Goldstein Daniel R, Uddin Mohib, Akbar Arne N, Gilroy Derek W
Division of Medicine, University College London, London, UK.
Division of Infection and Immunity, University College London, London, UK.
Nat Immunol. 2020 Jun;21(6):615-625. doi: 10.1038/s41590-020-0646-0. Epub 2020 Apr 6.
Increasing age alters innate immune-mediated responses; however, the mechanisms underpinning these changes in humans are not fully understood. Using a human dermal model of acute inflammation, we found that, although inflammatory onset is similar between young and elderly individuals, the resolution phase was substantially impaired in elderly individuals. This arose from a reduction in T cell immunoglobulin mucin receptor-4 (TIM-4), a phosphatidylserine receptor expressed on macrophages that enables the engulfment of apoptotic bodies, so-called efferocytosis. Reduced TIM-4 in elderly individuals was caused by an elevation in macrophage p38 mitogen-activated protein kinase (MAPK) activity. Administering an orally active p38 inhibitor to elderly individuals rescued TIM-4 expression, cleared apoptotic bodies and restored a macrophage resolution phenotype. Thus, inhibiting p38 in elderly individuals rejuvenated their resolution response to be more similar to that of younger people. This is the first resolution defect identified in humans that has been successfully reversed, thereby highlighting the tractability of targeting pro-resolution biology to treat diseases driven by chronic inflammation.
年龄增长会改变先天免疫介导的反应;然而,人类这些变化背后的机制尚未完全了解。利用急性炎症的人类皮肤模型,我们发现,尽管年轻人和老年人的炎症发作相似,但老年人的炎症消退阶段却严重受损。这是由于T细胞免疫球蛋白粘蛋白受体4(TIM-4)减少所致,TIM-4是一种在巨噬细胞上表达的磷脂酰丝氨酸受体,可实现对凋亡小体的吞噬,即所谓的胞葬作用。老年人TIM-4减少是由巨噬细胞p38丝裂原活化蛋白激酶(MAPK)活性升高引起的。给老年人服用口服活性p38抑制剂可挽救TIM-4表达,清除凋亡小体并恢复巨噬细胞的消退表型。因此,抑制老年人的p38可使其消退反应恢复活力,更类似于年轻人。这是在人类中发现的第一个已成功逆转的消退缺陷,从而突出了靶向促消退生物学以治疗由慢性炎症驱动的疾病的可操作性。
Genes Genomics. 2020-9
Immunol Rev. 2016-9
Exp Mol Med. 2025-9-1
Signal Transduct Target Ther. 2025-8-6
Exp Hematol. 2025-7-11
FASEB J. 2025-7-15
J Immunol. 2025-5-1
Nature. 2018-9-5
J Allergy Clin Immunol. 2017-11-17
Int J Mol Sci. 2017-7-17
Trends Endocrinol Metab. 2016-10-24